BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications.
The product was in-licensed from Fischer Pharmaceuticals and RAMOT, the technology transfer arm of the Tel Aviv University.
The product has CE Mark marketing approval in Europe, and BioLight is currently evaluating the clinical and regulatory efforts required to commercialize it elsewhere.
BioLight also was granted exclusive global rights, excluding Italy, by RAMOT to develop, manufacture and commercialize additional new ophthalmic therapies based on the product’s underlying technology. The technology, which protects the ocular surface and enhances the corneal re-epithelization process, was originally developed in the Tel-Aviv University.
In a statement, BioLight CEO, Suzana Nahum Zilberberg, said the global in-licensing agreement adds a fifth major ophthalmic product to the company’s pipeline.
While there have been a number of advances in understanding and treatment of DES over the past few years, she said there is no question that a significant unmet medical need remains.
“The potential synergies of pairing the new DES therapeutic product with our TeaRx multi-parameter diagnostic test for DES are both obvious and exciting,” she added.
